Stock comparison
Edwards Lifesciences
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EW
Edwards Lifesciences
Market cap
$49.39B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Edwards Lifesciences EW
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EW | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 65C | GMAB |
| Benjamin Graham | 89A | 64C | EW |
| Philip Fisher | 62C | 48D | EW |
| Peter Lynch | 26F | 25F | EW |
| Joel Greenblatt | 54C | 76B | GMAB |
| Charlie Munger | 71C | 68C | EW |
| Terry Smith | 70B | 71C | GMAB |
Side-by-side metrics
| Metric | EW | GMAB |
|---|---|---|
| Market cap | $49.39B | $16.5B |
| P/E (TTM) | 43.2x | 6.2x |
| EV/EBIT | 27.6x | 12.0x |
| ROIC (TTM) | 12.06% | 43.78% |
| Gross margin | 78.01% | 93.88% |
| Net margin | 17.34% | 18.23% |
| Revenue CAGR 5y | 3.77% | -18.45% |
| EPS CAGR 5y | -6.52% | -23.48% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EW leads on
- Revenue CAGR 5y3.77%vs -18.45%+120%
- EPS CAGR 5y-6.52%vs -23.48%+72%
- Market cap$49.39Bvs $16.5B+67%
- Debt / Equity0.1xvs 0.1x+7%
GMAB leads on
- P/E (TTM)6.2xvs 43.2x+86%
- ROIC (TTM)43.78%vs 12.06%+72%
- EV/EBIT12.0xvs 27.6x+57%
- Gross margin93.88%vs 78.01%+17%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.